Sirt-1 activity in PBMC from patients with spondyloarthritis

Joint Bone Spine

Volumn 82, Issue 3, 2015, Pages 210-211

  Wendling, Daniel ^a,b   Delattre, Emilie ^a   Abbas, Wasim ^b   Guillot, Xavier ^a   Toussirot, Eric ^a,b   Herbein, Georges ^a,b  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b NONE   (France)

Author keywords

Cytokines; Epigenetics; Sirtuins; Spondyloarthritis

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; NONSTEROID ANTIINFLAMMATORY AGENT; SIRTUIN 1; SIRTUIN;

ADULT; ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; HUMAN; HUMAN CELL; LETTER; MALE; MIDDLE AGED; PERIPHERAL BLOOD MONONUCLEAR CELL; PROSPECTIVE STUDY; SPONDYLARTHRITIS; EPIGENETICS; GENETICS; OSTEOARTHRITIS; PATHOPHYSIOLOGY; PHYSIOLOGY;

EPIGENOMICS; HUMANS; OSTEOARTHRITIS; SIRTUINS;

EID: 84929292319     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2014.10.002     Document Type: Letter

References (10)

1. Gabay O., Sanchez C. Epigenetics, sirtuins and osteoarthritis. Joint Bone Spine 2012, 79:570-573.
2. Alvarez Y., Rodríguez M., Municio C., et al. Sirtuin 1 is a key regulator of the interleukin-12 p70/interleukin-23 balance in human dendritic cells. J Biol Chem 2012, 287:35689-35701.
3. Lee I.H., Yun J., Finkel T. The emerging links between sirtuins and autophagy. Methods Mol Biol 2013, 1077:259-271.
4. Abed É., Couchourel D., Delalandre A., et al. Low sirtuin 1 levels in human osteoarthritis subchondral osteoblasts lead to abnormal sclerostin expression which decreases Wnt/β-catenin activity. Bone 2014, 59:28-36.
5. Wendling D., Abbas W., Godfrin-Valnet M., et al. Resveratrol, a sirtuin 1 activator, increases IL-6 production by peripheral blood mononuclear cells of patients with knee osteoarthritis. Clin Epigenetics 2013, 5:10. 10.1186/1868-7083-5-10.
6. Toussirot E., Abbas W., Khan K.A., et al. Imbalance between HAT and HDAC activities in the PBMCs of patients with ankylosing spondylitis or rheumatoid arthritis and influence of HDAC inhibitors on TNF alpha production. PLoS One 2013, 8:e70939. [eCollection 2013]. 10.1371/journal.pone.0070939.
7. Wendling D., Vidon C., Abbas W., et al. Sirt1activity in peripheral blood mononuclear cells from patients with rheumatoid arthritis. Joint Bone Spine 2014, [pii: S1297-319X(14)00050-5]. 10.1016/j.jbspin.2014.02.006.
8. Wendling D., Herbein G. Sirt1 and osteoarthritis. Comments on the paper by Gabay et al.: "Sirt1-deficient mice exhibit an altered cartilage phenotype". Joint Bone Spine 2013, 81:104. [Joint Bone Spine. 2014].
9. Toussirot E., Wendling D., Herbein G. Biological treatments given in patients with rheumatoid arthritis or ankylosing spondylitis modify HAT/HDAC (histone acetyltransferase/histone deacetylase) balance. Joint Bone Spine 2014, on behalf of CIC-1431, [pii: S1297-319X(14)00055-4]. 10.1016/j.jbspin.2014.02.011.
10. Zhang R., Chen H.-Z., Liu J.-J., et al. SIRT1 suppresses activator protein-1 transcriptional activity and cyclooxygenase-2 expression in macrophages. J Biol Chem 2010, 285:7097-7110.